Sarafoglou Kyriakie, Forlenza Gregory P, Yaw Addo O, Kyllo Jennifer, Lteif Aida, Hindmarsh P C, Petryk Anna, Gonzalez-Bolanos Maria Teresa, Miller Bradley S, Thomas William
Department of Pediatrics, University of Minnesota Masonic Children's Hospital, Minneapolis, MN, USA.
Pediatric Endocrinology Barbara Davis Center, University of Colorado Denver, Denver, CO, USA.
Clin Endocrinol (Oxf). 2017 May;86(5):708-716. doi: 10.1111/cen.13313. Epub 2017 Mar 28.
To evaluate obesity and overweight in children with congenital adrenal hyperplasia (CAH) and associations with glucocorticoids, fludrocortisone and disease control. Adjusting body mass index-for-height-age (BMI ) percentile is proposed to correct misclassification of obese/overweight status in CAH children with advanced bone age and tall-for-age stature.
Longitudinal.
One hundred and ninety-four children with CAH seen from 1970 to 2013: 124 salt wasting (SW); 70 simple virilizing (SV); 102 females.
Body mass index (BMI) end-points were overweight (85-94 percentile) and obese (≥95 percentile).
Approximately 50% of the children had at least one BMI measurement ≥95 percentile and about 70% had at least one ≥85 percentile. Using BMI percentiles, obesity incidence decreased slightly in SW children (47-43%) and markedly in SV children (50-33%); however, overweight status was not reduced. Only 6% of SW and 1% of SV children were persistently obese (≥3 clinic visits) when BMI was applied, whereas overweight status persisted in 35% of SW and 33% of SV children. Most obesity or overweight when using BMI occurred before age 10 and there was no association with hydrocortisone (HC) or fludrocortisone dosing. Adiposity rebound for SW children occurred by 3·3 years and in SV females by age 3·8 years, over a year earlier than the adiposity rebound for healthy children.
Children with CAH are at higher risk for early onset obesity and overweight with or without using BMI but rates of persistent obesity were lower than previously reported. Careful HC dosing during early childhood is needed to prevent increased weight gain and an early adiposity rebound.
评估先天性肾上腺皮质增生症(CAH)患儿的肥胖和超重情况,以及与糖皮质激素、氟氢可的松和疾病控制的关联。建议调整身高年龄别体重指数(BMI)百分位数,以纠正骨龄提前和年龄别身材高大的CAH患儿肥胖/超重状态的错误分类。
纵向研究。
1970年至2013年期间诊治的194例CAH患儿:124例失盐型(SW);70例单纯男性化型(SV);102例女性。
BMI终点为超重(第85 - 94百分位数)和肥胖(≥第95百分位数)。
约50%的患儿至少有一次BMI测量值≥第95百分位数,约70%的患儿至少有一次≥第85百分位数。使用BMI百分位数时,SW患儿的肥胖发生率略有下降(47% - 43%),SV患儿显著下降(50% - 33%);然而,超重状态并未降低。应用BMI时,只有6%的SW患儿和1%的SV患儿持续肥胖(≥3次门诊就诊),而35%的SW患儿和33%的SV患儿超重状态持续存在。使用BMI时,大多数肥胖或超重发生在10岁之前,且与氢化可的松(HC)或氟氢可的松剂量无关。SW患儿的脂肪量反弹发生在3.3岁,SV女性患儿为3.8岁,比健康儿童的脂肪量反弹早一年多。
CAH患儿无论是否使用BMI,发生早发性肥胖和超重的风险均较高,但持续肥胖率低于先前报道。儿童期早期需要谨慎调整HC剂量,以防止体重增加过多和早期脂肪量反弹。